TABLE 2. Unadjusted IRs of breakthrough SARS‐CoV‐2 infections among vaccinated CLD patients.
| Patient Group | Total Person‐Months | No. (Breakthrough) Cases | Incidence Rate per 1000 Person‐Months (95% CI) |
|---|---|---|---|
| Unvaccinated—overall | 1915,799 | 26,676 | 13.9 (13.8–14.1) |
| CLD without cirrhosis | 1,390,120 | 20,058 | 14.4 (14.2–14.6) |
| CLD with cirrhosis | 525,679 | 6618 | 12.6 (12.3–12.9) |
| Partial vaccination—overall | 61,344 | 421 | 6.5 (5.9–7.2) |
| CLD without cirrhosis | 46,353 | 311 | 6.4 (5.7–7.1) |
| CLD with cirrhosis | 14,991 | 110 | 7.1 (5.9–8.6) |
| Full vaccination—overall | 222,899 | 1183 | 5.3 (5.0–5.6) |
| CLD without cirrhosis | 171,561 | 929 | 5.4 (5.1–5.8) |
| CLD with cirrhosis | 51,228 | 254 | 4.9 (4.4–5.6) |
| Additional/boosted—overall | 7897 | <70a | <8.6 (6.3–10.9)a |
| CLD without cirrhosis | 5790 | 50 | 8.3 (6.3–11.0) |
| CLD with cirrhosis | 2107 | <20a | <9.5 (6.1–14.7)a |
Note: EIRs were based on unadjusted Poisson regression models with robust SEs.
a
N3C policy requires all cells that contain fewer than 20 persons to be reported as <20 or censored.